Most cited papers from Idorsia (Switzerland)

Idorsia (Switzerland)

What are the most cited papers from Idorsia (Switzerland)?

The most cited paper from Idorsia (Switzerland) is "A heterogeneous single-atom palladium catalyst surpassing homogeneous systems for Suzuki coupling" (Zupeng Chen, Evgeniya Vorobyeva, Sharon Mitchell et al., 2018), with 659 citations. Next come "Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials" (248) and "Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial" (239).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 43 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	A heterogeneous single-atom palladium catalyst surpassing homogeneous systems for Suzuki coupling Zupeng Chen, Evgeniya Vorobyeva, Sharon Mitchell et al. · Nature Nanotechnology Open access	22 Jun 2018	659
2	Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials Emmanuel Jean-Marie Mignot, David W. Mayleben, Ingo Fietze et al. · The Lancet Neurology	19 Jan 2022	248
3	Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial Markus Peter Schlaich et al. · The Lancet Open access215 authors	7 Nov 2022	239
4	Small-molecule factor B inhibitor for the treatment of complement-mediated diseases Anna Schubart et al. · Proceedings of the National Academy of Sciences Open access	29 Mar 2019	221
5	Traditional and Digital Biomarkers: Two Worlds Apart? Lmar Marie Babrak, Joseph P. Menetski, Michael Rebhan et al. · Digital Biomarkers Open access	16 Aug 2019	190
6	Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis Frank Penkava et al. · Nature Communications Open access	21 Sep 2020	189
7	A workflow for deriving chemical entities from crystallographic data and its application to the Crystallography Open Database Antanas Vaitkus, Andrius Merkys, Thomas Sander et al. · Journal of Cheminformatics Open access	19 Dec 2023	155
8	Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder Yves A Dauvilliers, Gary K Zammit, Ingo Fietze et al. · Annals of Neurology	17 Jan 2020	149
9	Orbit Image Analysis: An open-source whole slide image analysis tool Manuel Stritt, Anna Katharina Stalder, Enrico Vezzali · PLoS Computational Biology Open access	5 Feb 2020	145
10	Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson’s disease Florian Lipsmeier, Kirsten I. Taylor, Ronald B. Postuma et al. · Scientific Reports Open access	15 Jul 2022	118
11	Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement Nicolas Guérard, Daniel Oder, Peter Nordbeck et al. · Clinical Pharmacology & Therapeutics	12 Jul 2017	117
12	The orexin story and orexin receptor antagonists for the treatment of insomnia Clemens Muehlan, Catherine Roch, Cédric Vaillant et al. · Journal of Sleep Research Open access	22 Apr 2023	116
13	Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions Christine Huynh, Jasper Dingemanse, Henriette E. Meyer zu Schwabedissen et al. · Pharmacological Research Open access	3 Aug 2020	114
14	Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder Dieter Kunz, Yves A Dauvilliers, Heike Beneš et al. · CNS Drugs Open access	9 Dec 2022	106
15	Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen et al. · Expert Opinion on Drug Metabolism & Toxicology	9 Sep 2020	102
16	Long-term use of benzodiazepines in chronic insomnia: a European perspective Michael Soyka, Imane Wild, Bérangère Caulet et al. · Frontiers in Psychiatry Open access	2 Aug 2023	98
17	Algorithm-aided engineering of aliphatic halogenase WelO5* for the asymmetric late-stage functionalization of soraphens Johannes Büchler, Sumire Honda Malca, David Patsch et al. · Nature Communications Open access	18 Jan 2022	94
18	Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension Paul E. Verweij, Parisa Danaietash, Bruno Flamion et al. · Hypertension Open access	17 Feb 2020	93
19	Self-assembled thermoresponsive nanostructures of hyaluronic acid conjugates for osteoarthritis therapy Pierre Maudens, Sophie Meyer, Christian Alexander Seemayer et al. · Nanoscale Open access	8 Dec 2017	90
20	Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort Yasmina Bauer, Simon de Bernard, Peter M. Hickey et al. · European Respiratory Journal Open access	17 Dec 2020	89
21	Microglial Homeostasis Requires Balanced CSF-1/CSF-2 Receptor Signaling Violeta Chiţu, Fabrizio Biundo, Gabriel G. L. Shlager et al. · Cell Reports Open access	Mar 2020	89
22	The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468 Alexander Treiber, Ruben de Kanter, Catherine Roch et al. · Journal of Pharmacology and Experimental Therapeutics Open access	29 Jun 2017	87
23	Nanocrystal–Polymer Particles: Extended Delivery Carriers for Osteoarthritis Treatment Pierre Maudens, Christian Alexander Seemayer, Cédric Thauvin et al. · Small Open access	12 Jan 2018	81
24	Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction Peter Sinnaeve, Gregor Fahrni, Dan Schelfaut et al. · Journal of the American College of Cardiology Open access	May 2020	79
25	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes Robert F. Storey, Paul Alfred Gurbel, Jurriën M. ten Berg et al. · European Heart Journal Open access	25 Oct 2019	79
26	Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia Catherine Roch, Giorgio Bergamini, Michel Alexander Steiner et al. · Psychopharmacology Open access	20 Aug 2021	75
27	Long‐term survival outcomes of patients with Niemann‐Pick disease type C receiving miglustat treatment: A large retrospective observational study Marc C. Patterson, William Sherman Garver, R. Giugliani et al. · Journal of Inherited Metabolic Disease Open access	23 Apr 2020	74
28	Computer-assisted mitotic count using a deep learning–based algorithm improves interobserver reproducibility and accuracy Christof Bertram et al. · Veterinary Pathology Open access	30 Dec 2021	73
29	Accelerated Development of the Dual Orexin Receptor Antagonist ACT‐541468: Integration of a Microtracer in a First‐in‐Human Study Clemens Muehlan, Jules A. A. C. Heuberger, Pierre‐Éric Juif et al. · Clinical Pharmacology & Therapeutics Open access	15 Feb 2018	71
30	Nanocrystals of a potent p38 MAPK inhibitor embedded in microparticles: Therapeutic effects in inflammatory and mechanistic murine models of osteoarthritis Pierre Maudens, Christian Alexander Seemayer, François Pfefferlé et al. · Journal of Controlled Release Open access	7 Mar 2018	68
31	Immunotherapy of glioblastoma explants induces interferon-γ responses and spatial immune cell rearrangements in tumor center, but not periphery Tala Shekarian et al. · Science Advances Open access	Jul 2022	67
32	Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists Uta Schilling, Jasper Dingemanse, Mike Ufer · Clinical Pharmacokinetics	13 Feb 2020	65
33	Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies Olivier Bezençon, Bibia Heidmann, Romain Siegrist et al. · Journal of Medicinal Chemistry Open access	8 Nov 2017	65
34	Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension Frederic Trensz, Céline Bortolamiol, Markus Kramberg et al. · Journal of Pharmacology and Experimental Therapeutics Open access	8 Jan 2019	59
35	A fully automated image analysis method to quantify lung fibrosis in the bleomycin-induced rat model Shanon Seger, Manuel Stritt, Enrico Vezzali et al. · PLoS ONE Open access	16 Mar 2018	59
36	Accuracy evaluation and addition of improved dihedral parameters for the MMFF94s Joël Wahl, Joël Freyss, Modest von Korff et al. · Journal of Cheminformatics Open access	7 Aug 2019	58
37	Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration Clemens Muehlan, Sander Brooks, Rob G. J. A. Zuiker et al. · European Neuropsychopharmacology	17 Jun 2019	58
38	Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial Ingo Fietze, Claudio L. Bassetti, David W. Mayleben et al. · Drugs & Aging Open access	13 Sep 2022	56
39	Recommendations for robust and reproducible preclinical research in personalised medicine Vibeke Fosse et al. · BMC Medicine Open access	8 Jan 2023	54
40	The burden of untreated insomnia disorder in a sample of 1 million adults: a cohort study Michael A. Grandner, Antonio Olivieri, Ajay Ahuja et al. · BMC Public Health Open access	3 Aug 2023	53
41	Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway Marion Anliker‐Ort, Jasper Dingemanse, John van den Anker et al. · Frontiers in Immunology Open access	10 Dec 2020	53
42	First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study Viktória Hermann, Anastas Zgurov Batalov, Svetlana A Smakotina et al. · Lupus Science & Medicine Open access	Oct 2019	53
43	Confidence and Prediction Intervals for Pharmacometric Models Anne Kümmel, Peter L. Bonate, Jasper Dingemanse et al. · CPT Pharmacometrics & Systems Pharmacology Open access	Feb 2018	52
44	The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ Katarina Zmajkovicova, Katalin Menyhart, Yasmina Bauer et al. · American Journal of Respiratory Cell and Molecular Biology	11 Dec 2018	51
45	The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders Christoph Boss, John Gatfield, Christine Brotschi et al. · ChemMedChem	16 Sep 2020	49
46	Influence of Glass Forming Ability on the Physical Stability of Supersaturated Amorphous Solid Dispersions Lasse Ingerslev Blaabjerg, Bulut Bulduk, Eleanor Lindenberg et al. · Journal of Pharmaceutical Sciences	13 Mar 2019	48
47	Scalable Synthesis of Trifluoromethylated Imidazo-Fused N-Heterocycles Using TFAA and Trifluoroacetamide as CF3-Reagents Gabriel Schäfer, Muhamed Ahmetovic, Stefan Abele · Organic Letters	21 Nov 2017	47
48	Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem Mike Ufer, Debra Kelsh, Kerri A. Schoedel et al. · SLEEP	4 Sep 2021	46
49	Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea Marie‐Laure Boof, Jasper Dingemanse, Katharina Lederer et al. · SLEEP	11 Dec 2020	46
50	Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Stacie A. Hudgens, Andrea Phillips-Beyer, Louise E. Newton et al. · Patient Open access	Nov 2020	46

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.